Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Threshold Pharmaceuticals, Inc.

http://www.thresholdpharm.com

Latest From Threshold Pharmaceuticals, Inc.

Parexel Execs On Obesity Drug Hurdles, Parexel GPT, India RWD Opportunity

Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.

Research & Development Clinical Trials

Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens

Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.

Deal Watch Business Strategies

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Deal Watch Business Strategies

Novo Pumps Up Heart Failure Prospects With Cardior Purchase

The Danish drugmaker is spending some of its semaglutide cash on a mid-stage RNA-based heart failure therapy developed by the German biotech.

M & A Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register